Addex Therapeutics Ltd (Addex) is a biopharmaceutical company that develops and commercialize orally available, small molecule drugs, called allosteric modulators against diseases with high unmet medical needs. The company develops therapeutic compounds for the treatment of rare diseases with orphan drug designation potential for the dipraglurant in PD-LID. The company operates through single segment that develops and discover small -molecule pharmaceutical products. Addex develops its drugs based on its proprietary allosteric modulator discovery technology platform that allows industrial scale high throughput screening, which can be adapted to a broad range of targets. Addex uses this platform to address receptors and other proteins that are undruggable through conventional drug discovery methods, which include G-Protein Coupled Receptors (GPCRs).

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Addex's research and development initiatives have been primarily focused on building a portfolio of proprietary drug candidates based on allosteric modulation. The company believes this has broad applicability across a wide range of biological targets and therapeutic areas. The primary focus has been on G-protein coupled receptors, or GPCR, targets implicated in neurological diseases. The company has developed a pipeline of proprietary clinical and preclinical stage drug candidates for diseases such as epilepsy, post-stroke sensorimotor recovery, traumatic brain injury recovery, Parkinson’s disease levo-dopa induced dikynesia, substance use disorder, and chronic cough. Some of these indications are classified as rare diseases that may allow for orphan drug designation by regulatory agencies in major commercial markets. In FY2024, the company incurred research and development costs of CHF0.8 million.